ReviewInfection and drug resistance2023
How Long Will It Take to Launch an Effective
Review in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bibliometric analysis ofFrontiers in microbiology · 2025Pooled it
- The research progress of gastric cancer vaccines: a narrative review.Translational cancer research · 2026Review
- VTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION.Arquivos de gastroenterologia · 2026Article
- Mechanism-matchedFrontiers in medicine · 2026Review
- Review
- Immunoinformatics-Based Multi-Epitope Vaccine Targeting Helicobacter Pylori.Cancer reports (Hoboken, N.J.) · 2026Article
- Applying principles of vaccine development to oncomicrobial vaccines.Blood advances · 2025Review
- Treatment with (R)-α-methylhistamine or IL4 stimulates mucin production and decreasesVirulence · 2025Article
- Towards EffectiveInternational journal of molecular sciences · 2025Review
- Review
- Article
- Immunoinformatic strategy for developing multi-epitope subunit vaccine against Helicobacter pylori.PloS one · 2025Article
- Outer membrane vesicles from genetically engineeredVirulence · 2024Article
- Developing a potent vaccine againstExpert reviews in molecular medicine · 2024Review
- Opportunities forMicroorganisms · 2024Review
- Targeted nanotherapeutics for the treatment of Helicobacter pylori infection.Journal of biomedical science · 2024Review
- Review of foodborne helicobacteriosis.Italian journal of food safety · 2024Review
- Current and Future Perspectives on the Management ofAntibiotics (Basel, Switzerland) · 2024Review
- Gastric Cancer Survivorship: Multidisciplinary Management, Best Practices and Opportunities.Journal of gastrointestinal cancer · 2024Review
- Pivotal role ofFrontiers in medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.